Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Betaferon

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

- PMLiVE

NICE recommends GSK’s Zejula for patients with ovarian cancer

In the UK there are over 40,000 women with ovarian cancer

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

- PMLiVE

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

Biogen and The Alzheimer's Association fear that the approach will unfairly exclude patients from therapies and create further healthcare inequities

- PMLiVE

Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy

The licence is worldwide and exclusive and may include future royalty payments

Lesson Learned from the Pandemic

Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links